L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Doberstein, Kai ^a   Milde Langosch, Karin ^b   Bretz, Niko P ^a   Schirmer, Uwe ^a   Harari, Ayelet ^c   Witzel, Isabell ^b   Ben Arie, Alon ^c   Hubalek, Michael ^d   Müller Holzner, Elisabeth ^d   Reinold, Susanne ^e   Zeimet, Alain G ^d   Altevogt, Peter ^a   Fogel, Mina ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c KAPLAN MEDICAL CENTER   (Israel)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

AR; Basal like; EMT; ER PR; Triple negative

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NERVE CELL ADHESION MOLECULE L1; PROGESTERONE RECEPTOR; MESSENGER RNA; PROTEIN BINDING; TUMOR MARKER;

ADULT; AGED; ARTICLE; BINDING SITE; CAMKK GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; L1CAM GENE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEURAL CELL ADHESION MOLECULE L1; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84924655417     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-958     Document Type: Article

References (35)

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007,13(15 Pt 1):4429-4434.
2. Oakman C, Viale G, Di Leo A: Management of triple negative breast cancer. Breast 2010,19(5):312-321. 10.1016/j.breast.2010.03.026
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000,406(6797):747-752. 10.1038/35021093
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001,98(19):10869-10874. 10.1073/pnas.191367098
5. Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature 2012,490(7418):61-70. 10.1038/nature11412
6. Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE: Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol 2013,26(7):955-966. 10.1038/modpathol.2012.244
7. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011,24(2):157-167. 10.1038/modpathol.2010.200
8. Kotsopoulos J, Narod SA: Androgens and breast cancer. Steroids 2012,77(1-2):1-9.
9. Chang C, Lee SO, Yeh S, Chang TM: Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 2014,33(25):3225-3234. 10.1038/onc.2013.274
10. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E: Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014,106(1):djt319. 10.1093/jnci/djt319
11. Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K: Androgen receptor status is a prognostic marker in non-Basal triple negative breast cancers and determines novel therapeutic options. PLoS ONE 2014,9(2):e88525. 10.1371/journal.pone.0088525
12. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, Tan PH: Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014,27(3):352-360.
13. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ, Tamimi RM, Ince TA: Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Investig 2014,124(2):859-870. 10.1172/JCI70941
14. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008,14(5):1368-1376. 10.1158/1078-0432.CCR-07-1658
15. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 2011,121(7):2750-2767. 10.1172/JCI45014
16. Schafer MK, Altevogt P: L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci 2010,67(14):2425-2437. 10.1007/s00018-010-0339-1
17. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P: L1CAM: a major driver for tumor cell invasion and motility. Cell Adhes Migr 2012,6(4):374-384. 10.4161/cam.20832
18. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A: L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008,8(11):1749-1757. 10.1517/14712598.8.11.1749
19. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003,362(9387):869-875. 10.1016/S0140-6736(03)14342-5
20. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Munch M, Muller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevogt P, Fogel M: Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010,220(5):551-561. 10.1002/path.2673
21. Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P: Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann Oncol 2012,23(7):1795-1802. 10.1093/annonc/mdr568
22. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Muller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M: L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013,105(15):1142-1150. 10.1093/jnci/djt144
23. Schroder C, Schumacher U, Fogel M, Feuerhake F, Muller V, Wirtz RM, Altevogt P, Krenkel S, Janicke F, Milde-Langosch K: Expression and prognostic value of L1-CAM in breast cancer. Oncol Rep 2009,22(5):1109-1117.
24. Cancer Genome Atlas Research N: Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA: Integrated genomic characterization of endometrial carcinoma. Nature 2013,497(7447):67-73. 10.1038/nature12113
25. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006,37(8):1000-1008. 10.1016/j.humpath.2006.03.014
26. Fogel M, Harari A, Muller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P: A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms. Int J Biol Markers 2014,29(2):e180-e183. 10.5301/jbm.5000055
27. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K, Altevogt P: Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000,275(20):15490-15497. 10.1074/jbc.275.20.15490
28. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ: Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 1989,86(1):327-331. 10.1073/pnas.86.1.327
29. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P: L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 2010, 11:64. 10.1186/1471-2199-11-64
30. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG: The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011,30(13):2719-2733. 10.1038/emboj.2011.158
31. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schafer H, Sebens S, Altevogt P: EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis 2012,33(10):1919-1929. 10.1093/carcin/bgs220
32. Shah PD, Gucalp A, Traina TA: The role of the androgen receptor in triple-negative breast cancer. Women's health 2013,9(4):351-360. 10.2217/whe.13.33
33. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK: Role of the androgen receptor in breast cancer and preclinical analysis of Enzalutamide. Breast Cancer Res 2014,16(1):R7. 10.1186/bcr3599
34. Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Muller-Holzner E, Bode PK, Tischler V, Altevogt P: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. BMC Cancer 2013, 13:156. 10.1186/1471-2407-13-156
35. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Muller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sultmann H, Altevogt P: Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget 2014,5(2):462-472.